Q4 2024 · 13F-HR
Venrock Adviser, LLCholdings as filed
Filed 2025-02-14 · accession 0001104659-25-014110
$1.46B
Reported value
37
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $384.7M | 26.4% | 8,493,321 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $109.0M | 7.48% | 12,762,462 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $90.6M | 6.22% | 4,026,331 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $76.2M | 5.23% | 989,985 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $74.4M | 5.11% | 3,882,709 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $63.7M | 4.37% | 3,285,620 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $62.5M | 4.29% | 2,685,448 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $61.7M | 4.24% | 3,220,130 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $52.9M | 3.63% | 6,249,731 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $51.2M | 3.51% | 2,173,913 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $44.3M | 3.04% | 5,684,411 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $40.7M | 2.79% | 16,216,216 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $38.0M | 2.61% | 1,744,373 | Common | SOLE |
| 91678A107 | UPB | UPSTREAM BIO INC | $37.7M | 2.59% | 2,295,319 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $35.5M | 2.43% | 4,394,527 | Common | SOLE |
| 29286M105 | — | ENGENE HOLDINGS INC | $33.6M | 2.30% | 5,046,414 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $24.9M | 1.71% | 592,411 | Common | SOLE |
| 04635X102 | CATBUSD | ASTRIA THERAPEUTICS INC | $22.0M | 1.51% | 2,457,348 | Common | SOLE |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $20.6M | 1.41% | 765,723 | Common | SOLE |
| 230031106 | CGEM | CULLINAN THERAPEUTICS INC | $16.8M | 1.15% | 1,379,965 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $16.4M | 1.13% | 2,952,371 | Common | SOLE |
| 04317A107 | ARTV | ARTIVA BIOTHERAPEUTICS INC | $16.2M | 1.11% | 1,609,569 | Common | SOLE |
| 59045L106 | — | MERSANA THERAPEUTICS INC | $14.7M | 1.01% | 10,257,790 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $9.9M | 0.68% | 1,345,780 | Common | SOLE |
| 03843E104 | AQST | AQUESTIVE THERAPEUTICS INC | $9.4M | 0.64% | 2,629,786 | Common | SOLE |
| 03828A101 | APLT | APPLIED THERAPEUTICS INC | $8.6M | 0.59% | 9,990,591 | Common | SOLE |
| G70077105 | PCSC | PERCEPTIVE CAP SOLUTIONS COR | $7.6M | 0.52% | 750,000 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $6.0M | 0.41% | 1,077,090 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $5.6M | 0.38% | 3,225,180 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $5.2M | 0.36% | 1,266,457 | Common | SOLE |
| G9TY5A101 | ZURA | ZURA BIO LTD | $5.1M | 0.35% | 2,023,166 | Common | SOLE |
| 15673T100 | IPSC | CENTURY THERAPEUTICS INC | $4.0M | 0.27% | 3,957,186 | Common | SOLE |
| G1933S101 | CASIF | CASI PHARMACEUTICALS INC | $2.8M | 0.19% | 987,259 | Common | SOLE |
| 87990A106 | TNYA | TENAYA THERAPEUTICS INC | $2.2M | 0.15% | 1,555,556 | Common | SOLE |
| 88032L605 | TENX | TENAX THERAPEUTICS INC | $1.3M | 0.09% | 208,333 | Common | SOLE |
| 38000Q102 | GLYCEUR | GLYCOMIMETICS INC | $747,000 | 0.05% | 3,000,000 | Common | SOLE |
| 45783C200 | TIL | INSTIL BIO INC | $633,349 | 0.04% | 33,177 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.